Drug intelligence / Profile preview

UriVa

Development stage: Unknown
Lead developer: Aytu BioPharma
Administration: Vaginal

Overview

UriVa is a patented, commercial-stage herbal supplement developed by Seipel Group and rebranded and marketed by Innovus Pharmaceuticals. It is indicated for the treatment of overactive bladder and urinary incontinence. Innovus Pharmaceuticals obtained exclusive rights to market the product, previously known as Urox®, aiming to expand its product line and increase sales through its direct-to-consumer platform.

Brand names: UriVa
Other names: Urox

Beyond the preview

Go deeper on UriVa.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UriVa.

Explore the full profile